A breakthrough study presented at The Liver Meeting by the American Association for the Study of Liver Diseases reveals that artificial intelligence (AI) can significantly improve early detection of Metabolic-Associated Steatotic Liver Disease (MASLD), a leading cause of liver disease. This study highlights how AI can enhance diagnosis by analyzing electronic health records (EHR). Such analysis can potentially save millions of lives through earlier intervention.
To combat the underdiagnosis of MASLD, researchers led by Dr. Ariana Stuart at the University of Washington have developed an AI algorithm capable of analyzing EHR imaging data. The algorithm identifies patients who meet the criteria for MASLD, even if they have not received an official diagnosis.
Dr. Stuart, a resident at the University of Washington, explained that this study does not reflect a shortcoming in primary care training. Instead, it demonstrates how AI can support medical professionals. This support addresses the limitations of traditional clinical workflows. Detecting MASLD early using AI algorithm prevents the disease’s progression. This progression could lead to more serious liver conditions, like cirrhosis or liver cancer.
THE PROBLEM: UNDERDIAGNOSIS OF MASLD
MASLD is closely linked to obesity, Type-2 diabetes, and high cholesterol. It is often undiagnosed in its early stages. This occurs even when the disease is detectable through clinical data. While approximately 4.5 million adults in the U.S. suffer from MASLD, a staggering 83% of patients who meet the diagnostic criteria go undiagnosed. This delay in diagnosis can result in progression to more severe liver conditions.
THE STUDY: AI IN ACTION
The study involved analyzing EHR data from three sites within the University of Washington Medical System. Out of 834 patients who met the diagnostic criteria for MASLD, only 137 patients had an official diagnosis in their medical records. This finding underscores the critical gap in identifying early-stage MASLD. The AI algorithm, nonetheless, managed to pinpoint those at risk, offering a proactive solution to a widespread problem.
THE IMPORTANCE OF EARLY DIAGNOSIS
MASLD often presents with minimal or no symptoms at first. This makes it challenging for physicians to diagnose without advanced imaging or lab work. Without early detection, patients are at risk of developing more severe liver conditions that can be harder to treat. The study underscores the need for prompt intervention. Timely action could dramatically improve patient outcomes. It could also reduce the long-term burden of liver disease.
LOOKING AHEAD: THE ROLE OF AI IN MEDICINE
Dr. Stuart’s presentation, “Artificial Intelligence for Early MASLD Identification in the Electronic Medical Record,” highlights the growing potential of AI. This potential is particularly evident in medical diagnostics. As AI technology continues to evolve, it could transform clinical practice. Its integration could revolutionize how diseases like MASLD are diagnosed. AI’s role in managing medical conditions might also change dramatically. By enhancing the ability to identify conditions early, AI could play a key role in improving patient care and reducing the global burden of liver disease.